Phenobarbitone Causing Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in a Child Previously Exposed to Long-Term Phenobarbitone as an Infant

Jin Ho Chong* and Mark Jean Aan Koh

KK Women’s and Children’s Hospital, Singapore

Abstract

DRESS is a serious adverse drug reaction. This case illustrates the importance of being vigilant for the occurrence of DRESS, when restarting high risk drugs in patients who had no reaction after a first exposure during infancy.

Keywords: DRESS; Phenobarbitone; Previous exposure

Case Report

An 8 year old Chinese boy had epilepsy and global development delay associated with underlying West syndrome. He first presented with infantile spasms at 5 months of age and was treated with phenobarbitone for seizure control. Phenobarbitone was well-tolerated then and he was asymptomatic. Vigabatrin and sodium valproate were subsequently added 6 months after phenobarbitone monotherapy was started as the seizures increased in frequency. Phenobarbitone was weaned off over another 2 weeks. His seizures became well-controlled and all antiepileptic medications were discontinued from 3 years of age. 5 years later, generalised seizures recurred and sodium valproate was restarted and it was switched to phenobarbitone 4 months later for better seizure control.

1 month after restarting phenobarbitone, he presented with fever reaching a maximum of 39.5 degree celcius, vomiting and rash for 1 week with no other significant localising symptom. He had pruritic edema and erythema, which then progressed caudally to become a generalised pruritic erythematous maculopapular exanthema with some scaling. There was no lymphadenopathy, hepatomegaly or mucosal involvement. Full blood count showed eosinophilia and presence of atypical lymphocytes, 1 internal organ involvement. 2 systems which are the most commonly affected [6]. Other mechanisms may include the accumulation of arene toxic metabolites [6], detoxification defects, slow acetylation and abnormal immune responses [2].

Based on the RegiSCAR scoring system (fever greater than 38 degrees celcius, rash with edema and scaling involving 50% of body surface area, presence of eosinophilia and atypical lymphocytes, 1 internal organ involvement, negative investigation results from other potential causes and later on, resolution after more than 15 days), a diagnosis of DRESS syndrome secondary to phenobarbitone was made. Phenobarbitone was switched to levetiracetam. He responded to systemic corticosteroids and supportive liver protective measures. He eventually made a full recovery and was discharged after more than 2 weeks. On review, the rash and raised transaminase levels resolved. His dose of prednisolone was tapered over 4 months.

Discussion

Our patient did not develop DRESS as an infant despite a long latency period but developed DRESS many years later upon re-exposure. This is rarely reported. There is no data regarding the need for prior sensitization by drugs, on a separate occasion before DRESS develops. DRESS is known to occur 2-6 weeks after starting the drug for the first time, with more severe symptoms upon re-exposure. Han Chinese with HLAB*5801 who took allopurinol may develop DRESS [1]. This genetic predisposition was not evaluated in our patient.

DRESS rarely occurs in infants. We postulate that this may be due to a less mature immune system or the lack of exposure to HHV6, [2] Epstein - Barr virus or Cytomegalovirus in infancy. An 11 month old infant with HHV-6 infection and encephalopathy treated with phenobarbitone developed DRESS [3] and recovered from it. Another 3 month old infant who developed DRESS 2 weeks after starting Phenobarbitone subsequently died. In contrast, all her viral serologies, including HHV-6, were negative [4]. Hence although there may be a role of HHV-6 reactivation, leading to DRESS [5], it is clearly not the only pathomechanism as our patient had a negative HHV-6 serology.

As the mortality rate of DRESS can reach up to 10%, diagnosing DRESS early is crucial in order to discontinue the offending drug [7] and commence steroid therapy early [8]. Our patient was diagnosed early as he was taking 1 of the classical aromatic anticonvulsants [2] which was started a month before his symptoms, which was within the latency period for the onset of DRESS. He also had haematological and hepatic involvement, 2 systems which are the most commonly affected [6].

Pitfalls of diagnosing DRESS early include the suspicion of infectious diseases, including Epstein-Barr virus, Cytomegalovirus,

*Corresponding author: Dr. Jin Ho Chong, KK Women’s and Children’s Hospital, Singapore, Tel: +65 6225 5554; E-mail: chong.jin.ho@singhealth.com.sg

Received: November 02, 2015; Accepted: May 15, 2016; Published: May 18, 2016

Copyright: © 2016 Chong JH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Measles [9], parvovirus and Streptococcal pharyngitis [6]. Indeed, 13 out of 26 mainly adult DRESS patients [7] and 22 out of 32 paediatric DRESS patients [6] in retrospective reviews had infectious diseases as the initial primary diagnosis. Complicating matters, 15.6% of paediatric patients had proven concomitant infections with DRESS [6] and DRESS can result in variable symptoms from other organ systems which may further confound the diagnosis [1,6]. Other differential diagnoses include Kawasaki disease, serum sickness [9] and other severe drug-related dermatologic disorders such as erythroderma [8]. These differentials would have some clinical features and laboratory findings which do not match DRESS.

As not all physicians are familiar with DRESS [1], this case serves as a timely reminder to be vigilant for the occurrence of a severe drug reaction, such as DRESS, when restarting high risk drugs in patients who had no reaction despite a first exposure during infancy. Other than aromatic anticonvulsants, culprit drugs can include allopurinol, sulphonamides and antibiotics like vancomycin and minocycline [1].

References
1. Kardaun S, Sekula P, Valeyrile L, Liss Y, Chu Y, et al. (2013) Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. The British journal of dermatology 169 :1071-1080.
2. Husain Z, Reddy B, Schwartz R (2013) Dress syndrome: Part I. Clinical perspectives. Journal of the American Academy of Dermatology 68: 693.
3. Saida S, Yoshida A, Tanaka R, Abe J, Hamahata K, et al. (2010) A case of drug-induced hypersensitivity syndrome-like symptoms following HHV-6 encephalopathy. Allergology international 59: 83-86.
4. Chen C, Huang C, Wang C, Lin Y (2003) Fatal anticonvulsant hypersensitivity syndrome in an infant. European journal of pediatrics 162: 893-894.
5. Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, et al. (2011) The dress syndrome: a literature review. The American journal of medicine 124: 588-597.
6. Newell D, Moinfar M, Mancini J, Nopper J (2009) Retrospective analysis of 32 pediatric patients with anticonvulsant hypersensitivity syndrome (ACHSS). Pediatric dermatology 26: 536-546.
7. Lee Y, Walsh S, Creamer D (2012) Initial presentation of dress: often misdiagnosed as infections. Archives of dermatology 148: 1085-1087.
8. Husain Z, Reddy Y, Schwartz A (2013) Dress syndrome: Part II. Management and therapeutics. Journal of the American Academy of Dermatology 68: 18-20.
9. Fernando S (2014) Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome. The Australasian journal of dermatology 55: 15-23.